A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Howard A. Burris,Manish R. Patel,Daniel C. Cho,Jeffrey Melson Clarke,Martin Gutierrez,Tal Z. Zaks,Joshua Frederick,Kristen Hopson,Kinjal Mody,Alverina Binanti-Berube,Céline Robert-Tissot,Bree Goldstein,Ben Breton,Jing Sun,Shan Zhong,Scott K. Pruitt,Karen N. Keating,Robert S. Meehan,Justin F. Gainor

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

2019

Howard A. Burris
Manish R. Patel
Daniel C. Cho
Jeffrey Melson Clarke
Martin Gutierrez
Tal Z. Zaks
Joshua Frederick
Kristen Hopson
Kinjal Mody
Alverina Binanti-Berube
Céline Robert-Tissot
Bree Goldstein
Ben Breton
Jing Sun
Shan Zhong
Scott K. Pruitt
Karen N. Keating
Robert S. Meehan
Justin F. Gainor

2523Background: T-cell targeting of mutation-derived epitopes (neoantigens) has been demonstrated to drive anti-tumor responses. Immunizing patients against such neoantigens in combination with a c...

Keywords:

Oncology
Immunogenicity
Pembrolizumab
Pathology
Medicine
Tolerability
Internal medicine
Epitope
safety tolerability
multicenter study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations